Harmony Biosciences Holdings Inc (HRMY)
28.81
-0.58
(-1.97%)
USD |
NASDAQ |
Apr 23, 16:00
28.81
0.00 (0.00%)
After-Hours: 16:51
Harmony Biosciences Holdings Cash from Investing (TTM): -46.44M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -46.44M |
| September 30, 2023 | -57.27M |
| June 30, 2023 | -88.90M |
| March 31, 2023 | -103.58M |
| December 31, 2022 | -141.83M |
| September 30, 2022 | -94.94M |
| June 30, 2022 | -62.58M |
| March 31, 2022 | -40.34M |
| December 31, 2021 | -100.30M |
| Date | Value |
|---|---|
| September 30, 2021 | -102.30M |
| June 30, 2021 | -102.20M |
| March 31, 2021 | -102.01M |
| December 31, 2020 | -2.002M |
| September 30, 2020 | -77.04M |
| June 30, 2020 | -77.07M |
| March 31, 2020 | -77.12M |
| December 31, 2019 | -127.15M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-141.83M
Minimum
Dec 2022
-2.002M
Maximum
Dec 2020
-82.53M
Average
-88.90M
Median
Jun 2023
Cash from Investing (TTM) Benchmarks
| Amylyx Pharmaceuticals Inc | 92.05M |
| Exelixis Inc | -26.96M |
| Insmed Inc | -223.60M |
| Arcturus Therapeutics Holdings Inc | -2.901M |
| Ultragenyx Pharmaceutical Inc | 168.00M |